Osivax
Lyon, FR · Founded 2017 · 60 employees on LinkedIn · 3 known investors
Osivax develops vaccines targeting conserved internal viral structures to provide broader and longer-lasting protection against influenza, leveraging its proprietary oligoDOM technology platform. The company originated from research co-developed with the University of Oxford and is supported by public health foundations and pharmaceutical partners.
Founders & leadership
Osivax was founded in 2017 by Alexandre Le Vert, Dr Florence Nicolas, and Dr Fergal Hill.
AL
Alexandre Le VertExecutive Chairman & Co-Founder
DF
Dr Florence NicolasChief Scientific Officer & Co-Founder
DF
Dr Fergal HillCo-founder
Investors · 3
Frequently asked questions
- What does Osivax do?
- Osivax develops vaccines targeting conserved internal viral structures to provide broader and longer-lasting protection against influenza, leveraging its proprietary oligoDOM technology platform. The company originated from research co-developed with the University of Oxford and is supported by public health foundations and pharmaceutical partners.
- Who founded Osivax?
- Osivax was founded by Alexandre Le Vert, Dr Florence Nicolas, Dr Fergal Hill in 2017.
- Who are Osivax's investors?
- Osivax's investors include Wellcome Trust, Start Capital, CAP HORN VC.
- Where is Osivax headquartered?
- Osivax is headquartered in Lyon, FR.